IF by specialty › Oncology
Journal for ImmunoTherapy of Cancer — Impact Factor
The 2025 Impact Factor of Journal for ImmunoTherapy of Cancer is 11.7 (Q1 in Oncology; fully open access).
- Impact Factor
- 11.7 JCR 2025
- JCR category
- Oncology
- Quartile
- Q1 in Oncology
- Publisher
- BMJ (SITC)
- Open access
- fully open access
- IF source
- oncodaily.com
Position within the field
Ranked 14 of the 42 journals in Oncology on this site (top 50%).
Oncology journals with a similar Impact Factor
- Clinical Cancer Research IF 10.9
- Cancer Treatment Reviews IF 10.6
- ESMO Open IF 10.6
- European Journal of Cancer IF 7.9
- British Journal of Cancer IF 7.8
- Journal of the National Cancer Institute IF 7.7
About this value
The Journal Impact Factor of Journal for ImmunoTherapy of Cancer (JCR 2025, released June 2026) is 11.7. Values are compiled by cross-checking figures published by publishers and societies against public aggregators; this is not a reproduction of Clarivate Journal Citation Reports™. Confirm the current value on the publisher's page or in JCR before deciding where to submit. The quartile (Q1–Q4) is the journal's relative position within its JCR category; Q1 means the top 25%.
Last updated September 2026. Report errors via the contact form. Other journals in the same category: Oncology.